Breakthrough in Migraine Research: LUMC Develops Personalized Prediction


Leiden, December 6, 2025, 12:15 PM – by Robbert Beurse – Every day, around 70,000 people in the Netherlands experience a migraine attack. The condition ranks among the five most disabling diseases worldwide and can completely disrupt daily life. Researchers at Leiden University and LUMC are now developing an innovative method to predict migraine attacks on an individual level, a step toward truly personalized treatment.

Professor of Neurology Gisela Terwindt: “The societal impact of migraine is enormous. We know that hormones, stress, and sleep deprivation can play a role, but the precise triggers vary from person to person. That’s exactly what makes migraine so unpredictable. With this research, we aim to better understand these individual patterns.”

Migraine occurs three times more frequently in women than in men. For patients, an attack often means that work, study, or social activities come to an abrupt halt. Terwindt’s team is developing methods to build predictive models based on personal data. Lifestyle factors, brain activity, and smartphone data are combined with artificial intelligence (AI) to gain insight into each patient’s unique triggers.

“We hope that in the future, people can be warned in time about an impending attack, allowing them to respond effectively or even prevent it,” says Terwindt. Her research is supported by the Leiden University Fund (LUF).

LUMC is the only academic hospital in the Netherlands that focuses specifically on headache research.


  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…

  • VarmX recognised with two prestigious industry award nominations

    Leiden-based biotech company VarmX has received two industry award nominations recognising its scientific approach and strategic partnership with CSL. VarmX has been shortlisted for the 2026 Prix Galien USA “Best Startup” Award, which recognises early-stage companies developing novel therapeutic approaches.…